Key Highlights

  • Proteomics International announced a national rollout of PromarkerD and PromarkerEso through Healius, scheduled to go live on 26 October 2026.
  • Initial Australian patient prices are $495 for PromarkerD and $997 for PromarkerEso, on a private-pay basis.
  • The company said commercial availability of Promarker Endo is targeted for January to March 2027.

Proteomics International Laboratories (ASX:PIQ) has announced the national rollout of two of its Promarker diagnostic tests, PromarkerD and PromarkerEso, through its exclusive Australian pathology distribution partner, Healius Limited (ASX:HLS). The company said the rollout and supporting systems are scheduled to go live on Monday 26 October 2026, extending a controlled market release that began in September.

According to the company, the controlled release was announced on 14 September 2026 and ran through the Healius network in Western Australia and the Northern Territory. The national announcement, dated 23 October 2026, extends availability to the rest of the country. From 26 October, Healius collection centres are expected to accept patients for blood collection and to process payments for the tests.

Proteomics International said the two tests carry initial Australian patient prices, previously announced, of $495 for PromarkerD and $997 for PromarkerEso. Both are available on a private-pay basis at the outset. The announcement does not describe the clinical purpose of either test; it identifies only a third product, Promarker Endo, as intended for endometriosis.

Who does what

The company said the arrangement divides responsibilities between the two parties. Proteomics International performs the laboratory testing at its NATA-accredited Facility and provides clinical reporting, scientific and medical support, and quality and regulatory compliance. Healius supports specimen collection and pathology distribution and engages with clinicians through its national network.

Field sales teams have been trained on both tests, including their intended clinical uses and the processes for accessing them. The two companies have also agreed joint sales and Marketing plans intended to build clinician awareness, education, referrals and patient access.

David Morris, chief executive and managing director of Proteomics International, and Anthea Muir, Healius group executive for customer and commercial, are quoted in the release.

Promarker Endo to follow

The company said the rollout systems and processes are also expected to support the introduction of Promarker Endo. It reported that model refinement and independent validation of the endometriosis test were completed on 13 October 2026. Commercial availability is targeted for the third quarter of the 2027 financial year, which covers January to March 2027, and is subject to clinical deployment and applicable quality, accreditation and regulatory requirements.

Revenue not yet quantified

Proteomics International stated that Revenue under the distribution agreement cannot be reliably estimated at this time because the portfolio is at an early stage of commercialisation. No revenue figures, Volume targets or Margin information are given in the announcement.

Conditions and risks

The company said outcomes depend on a number of factors, including implementation timing, clinician adoption, patient utilisation, reimbursement, regulatory requirements, study outcomes and market conditions. The tests are initially private-pay only. The release contains forward-looking statements, and the dates it gives for Promarker Endo are targets.

Confirmed dates

Proteomics International (ASX:PIQ) gave the following dates: the 26 October 2026 go-live, with Healius collection centres taking patients and payments from that day, and the January to March 2027 target window for Promarker Endo. The announcement sets out no further dates.